title: LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma.
abstract: This study identified LTBP-2 as a pleiotropic tumor suppressor in nasopharyngeal carcinoma, which safeguards against critical malignant behaviors of tumor cells. LTBP-2 expression was significantly decreased or lost in up to 100% of NPC cell lines (7/7) and 80% of biopsies (24/30). Promoter hypermethylation was found to be involved in LTBP-2 silencing. Using a tetracycline-regulated inducible expression system, we unveiled functional roles of LTBP-2 in suppressing colony formation, anchorage-independent growth, cell migration, angiogenesis, VEGF secretion, and tumorigenicity. Three-dimensional culture studies suggested the involvement of LTBP-2 in maintenance of tumor cell dormancy in a growth factor favorable microenvironment.
authors: Division of Life Science, Hong Kong University of Science and Technology, Hong Kong Special Administrative Region.
authors: Han
authors: H
authors: Chen
authors: Josephine Mun Yee
authors: JM
authors: Ko
authors: Victor Chun Lam
authors: VC
authors: Wong
authors: Marko
authors: M
authors: Hyytiainen
authors: Jorma
authors: J
authors: Keski-Oja
authors: Daniel
authors: D
authors: Chua
authors: John M
authors: JM
authors: Nicholls
authors: Florence Man Fung
authors: FM
authors: Cheung
authors: Anne Wing Mui
authors: AW
authors: Lee
authors: Dora Lai-Wan
authors: DL
authors: Kwong
authors: Pui Man
authors: PM
authors: Chiu
authors: Eugene R
authors: ER
authors: Zabarovsky
authors: Sai Wah
authors: SW
authors: Tsao
authors: Qian
authors: Q
authors: Tao
authors: Rebecca
authors: R
authors: Kan
authors: Stephen Ho Kin
authors: SH
authors: Chan
authors: Eric J
authors: EJ
authors: Stanbridge
authors: Maria Li
authors: ML
authors: Lung
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D002277:Carcinoma; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation; D000077209:Decitabine; D015536:Down-Regulation / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D053779:Latent TGF-beta Binding Proteins / Q000235:genetics* / Q000378:metabolism*; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000098:blood supply / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism; D011401:Promoter Regions, Genetic; D059016:Tumor Microenvironment; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D006877:Hydroxamic Acids; C509035:LTBP2 protein, human; D053779:Latent TGF-beta Binding Proteins; D025521:Tumor Suppressor Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C012589:trichostatin A; D000077209:Decitabine; D001374:Azacitidine